zoledronic acid
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Trial Timeline
Nov 1, 2004 → Nov 1, 2007
NCT ID
NCT00099541About zoledronic acid
zoledronic acid is a approved stage product being developed by Novartis for Non-Small-Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00099541. Target conditions include Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant.
What happened to similar drugs?
6 of 20 similar drugs in Non-Small-Cell Lung Cancer were approved
Approved (6) Terminated (6) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01197300 | Phase 3 | Completed |
| NCT01087008 | Approved | Completed |
| NCT01004510 | Phase 2 | Terminated |
| NCT00909961 | Phase 3 | Completed |
| NCT00966992 | Phase 2 | Terminated |
| NCT00760370 | Phase 2 | Completed |
| NCT00774020 | Approved | Completed |
| NCT00740129 | Approved | Completed |
| NCT00745485 | Approved | Completed |
| NCT00477217 | Phase 2 | Withdrawn |
| NCT00622505 | Approved | Completed |
| NCT00982124 | Phase 3 | Completed |
| NCT01218035 | Approved | Completed |
| NCT00434447 | Approved | Completed |
| NCT00424983 | Phase 1 | Completed |
| NCT00391950 | Phase 3 | Terminated |
| NCT00361595 | Pre-clinical | Completed |
| NCT00334139 | Approved | Completed |
| NCT00391690 | Approved | Completed |
| NCT00375427 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer